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Summary. The four regulatory subunits (R1A, R1B,
R2A, R2B) of protein kinase A (PKA) are differentially
expressed in several cancer cell lines and exert distinct
roles in both cell growth and cell differentiation control.
Mutations of the PRKAR1A gene have been found in
patients with Carney complex and in a minority of
sporadic anaplastic thyroid carcinomas. The aim of the
study was to retrospectively evaluate the expression of
different PKA regulatory subunits in benign and non
benign human thyroid tumours and to correlate their
expression with clinical phenotype. 
Immunohistochemistry demonstrated a significant
increase in PRKAR2B expression in both differentiated
and undifferentiated (anaplastic) thyroid tumors in
comparison with normal thyroid tissues. Conversely, a
significant increase in PRKAR1A expression was only
demonstrated in undifferentiated thyroid carcinomas in
comparison with normal thyroid tissue and differentiated
thyroid tumors. In thyroid cancers without lymph nodal
metastases PRKAR1A expression was higher in tumours
of more than 2 cm in size (T2 and T3) compared to
smaller ones (T1). 
In conclusion, our data shows that an increased
PRKAR1A expression is associated with aggressive and
undifferentiated thyroid tumors.
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Introduction
Evidence from in vitro studies and naturally
occurring human diseases indicate that thyroid cell
growth is deeply influenced by intracellular cAMP levels
(Feliciello et al., 2000; Dremier et al., 2002; Horvath et
al., 2009). In particular, mutations of the stimulatory Gs
protein gene and TSH receptor leading to the
constitutive activation of adenylyl cyclase have been
found in a small subset of thyroid toxic adenomas
(Moretti et al., 2000). Recently, genetic defects
downstream from cAMP production and affecting cAMP
degradation have been recognized. In particular,
inactivating mutations and variants of phospho-
diesterases, i.e. PDE11A, have been implicated in
endocrine tumorigenesis while PDE8B polymorphisms
have been proposed to be involved in the regulation of
TSH levels (Horvath et al., 2006, 2009, 2010a,b). 
Recently, genetic defects downstream from cAMP
production and affecting PKA complex have been
identified in endocrine disorders, associated with benign
and malignant neoplasia (Kirschner et al., 2000; Moretti
et al., 2000; Sandrini et al., 2002; Porcellini et al., 2003;
Lania et al., 2004; Mantovani et al., 2009; Horvath et al.,
2010a; Pringle et al., 2012). In mammalian cells there
are two types of PKA, PKA1 and PKA2, which are
distinguished by 4 different regulatory subunits (R1A,
R1B, R2A and R2B) that differ in tissue distribution,
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subcellular localization and biological properties.
Dramatic changes in the proportion of R1 and R2
subunits during ontogenic development, differentiation
processes and neoplastic transformation indicate distinct
roles for these isoenzymes in growth control. In
particular, R1 subunits seem to be primarily involved in
cell proliferation while R2 subunits relate to tissue
differentiation (Cho-Chung et al., 1995). 
Carney complex is most commonly caused by
mutations in the PRKAR1A gene on chromosome 17q23-
q24 and inactivating germline mutations of this gene are
found in 70% of people with Carney complex.
Few data on the impact of PKA1 and PKA2
activation and R1 and R2 subunits expression on thyroid
cell differentiation and growth are available.
Experiments on mouse fibroblasts showed that the
expression of PRKAR2B was able to confer TSH-cAMP
dependent growth (Porcellini et al., 2003). Similarly, the
essential role of PRKAR2B on gene transcription and
proliferation was confirmed in FRTL5 cells (Sandrini et
al., 2002). Analyses on human cancer cell lines, i.e. NPA
(melanoma) and ARO (colonic carcinoma) cells, pointed
to a possible loss of PRKAR2B expression and an anti-
proliferative action of PRKAR1A activation in these
systems (Calebiro et al., 2006). 
Moreover, a tissue-specific knockout of PRKAR1A
thyroid resulted in hyperthyroid mice that developed
follicular thyroid neoplasms, including follicular
carcinomas in over 40% of animals (Pringle et al., 2012),
and downregulated PRKAR1A gene showed thyroid
findings in Carney complex patients, supporting its role
as a candidate tumour suppressor gene (Griffin et al.,
2004).
The aim of the study was to retrospectively evaluate
the expression of different PKA regulatory subunits in
benign and non benign human thyroid tumours and to
correlate their expression with clinical phenotype, in
order to demonstrate whether PRKAR1A and
PRKAR2B can be useful markers of malignancy for
thyroid cancer.
Materials and methods
Patients
In this study we retrospectively evaluated 6 nodular
hyperplasia, 16 follicular adenomas, 12 follicular
carcinomas (4 males and 8 females, age 51±11 years), 15
papillary carcinomas (4 males and 11 females, age
49±18 years) as well as 4 undifferentiated (anaplastic)
thyroid carcinomas (3 males and 1 female, age 66±9
years). For comparison, 10 normal specimens, collected
as far as possible from neoplastic lesions of patients
surgically resected for thyroid tumor, were included in
the analysis. After surgical resection, all tissues were
promptly formalin-fixed and paraffin embedded. 
Staging of neoplastic lesions was accomplished
according to the last edition of TNM (VII edition, 2009),
and patient characteristics are summarized in Table 1. A
paraffin block of the lesion representative of each case
was selected. Four sections, 3 micrometers-thick, were
cut for standard hematoxylin-eosin and immunohisto-
chemical staining. 
Immunohistochemistry
Specific monoclonal antibodies for PRKAR1A, and
PRKAR2B were used (BD Transduction Laboratories,
Lexington, United Kingdom) and antigen-antibody
detection was performed with the DAKO ChemMate En
Vision detection kit (DAKO A/S, Glostrup, Denmark)
according to the manufacturer ’s instructions as
previously described (Lania et al., 2004). Sections were
stained with 3,3’-diaminobenzidine substrate and
quickly counterstained with Meyer hematoxylin. Slides
were finally prepared for light microscopy examination.
Normal human adrenal tissue was used as positive
control, whereas for negative ones either the primary
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Table 1. Clinical and immunohistochemical characteristics of patients
affected with malignant thyroid lesions.
Cases Age Sex TNM Stage R1A score R2B score
FC1 67 F pT3N0 III 1 0
FC2 49 M pT3N0 III 6 0
FC3 42 F pT3N0 I 3 10
FC4 49 F pT3N0 III 6 0
FC5 52 F pT3N0 III 6 0
FC6 66 M pT2N0 II 4 9
FC7 60 M pT3N0 II 6 9
FC8 40 F pT3N0 I 1 9
FC9 30 M pT3N0 I 1 9
FC10 54 F pT2N0 II 3 9
FC11 59 F pT2N0 II 1 9
FC12 42 F pT1N0 I 2 9
PC1 80 M pT1N0 I 4 0
PC2 35 F pT1N1 I 6 1
PC3 58 F pT3N0 III 1 0
PC4 74 F pT2N0 II 6 0
PC5 70 M pT3N0 III 2 0
PC6 61 M pT3N1 III 6 1
PC7 32 F pT1N1 I 6 0
PC8 52 F pT1N0 I 1 9
PC9 56 F pT1N0 I 1 9
PC10 23 F pT1N0 I 1 9
PC11 43 F pT3N1 I 1 9
PC12 27 F pT3N1 I 4 9
PC13 31 F pT3N0 I 1 9
PC14 42 F pT3N1 I 2 9
PC15 60 M pT1N0 I 1 9
AC1 53 M pT4N3 IV 9 0
AC2 74 M pT4N4 IV 6 3
AC3 65 M pT4N4 IV 9 9
AC4 72 F pT4N4 IV 9 9
PKAR1Aand PKAR2B immunoreactivities were graded according to an
immunohistochemical score (range from 0 to 9 units) that is the product
of the percentage of positive cells for the intensity of the staining (see
Material and Methods). FC, follicular carcinoma; PC, papillary
carcinoma; AC, anaplastic carcinoma.
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antibody was omitted or an unrelated mouse monoclonal
antibody was employed. Briefly, PRKAR1A and
PRKAR2B immunoreactivities were graded according to
an immunohistochemical score (IHC score; range: 0-9
units) that takes into account both the percentage of
positive cells and the staining intensity. At least 400 cells
in the main representative high power field were
considered for each case and the percentage of positive
cells was estimated (0-30% = 1; 31-60% = 2; 61-100% =
3). The staining grade varied from 0 to 3, following
these criteria: 0 = absence of immunoreactivity, 1 =
weak, 2 = medium intensity and 3 = strong reactivity.
The IHC score was then computed by multiplying the
two values for each sample.
Three authors (SF, VV, ADG) looked at and graded
the specimens for all antibodies under study
independently. When the authors were discordant, the
section was revised and an agreement was achieved.
Statistical analysis
For statistical analysis, MedCalc software was used.
For two samples or group comparison the nonparametric
Mann-Whitney U or the Kruskal-Wallis tests were used,
respectively. The results are expressed as the mean ±
SEM. P values less than <0.05 were accepted as
statistically significant. 
Results
PRKAR1A expression 
PRKAR1A protein was expressed in all the normal
or pathological thyroid samples analyzed, with a general
upregulation of PRKAR1A in thyroid adenomas (p<0.05
by Kruskal-Wallis test) and carcinomas compared to
normal gland (p<0.05 by Kruskal-Wallis test; Fig. 1a).
Specifically, PRKAR1A was overexpressed in either
follicular or papillary thyroid carcinomas (average score
3.3±0.6 and 2.9±0.5, respectively) compared to
hyperplasia or follicular adenomas (score average =
1.3±0.2 and 2.2±0.2, respectively), peaking with the
highest staining in undifferentiated carcinomas (mean
immunohistochemistry score = 8.3±0.7; p<0.0001 by
Kruskal-Wallis test; Fig. 1A). The immunoreactivity for
PRKAR1A in all thyroid carcinomas was diffuse and
anaplastic carcinomas showed an intense and broaden
protein expression. 
PKRAR2B expression
Weak or no immunoreactivity for PRKAR2B was
found in normal thyroid samples (mean immunohisto-
chemistry score 0.7±0.3), and this pattern of
immunoreactivity was similar to that observed in
nodular hyperplasia (mean immunohistochemistry score
0.4±0.2; Fig 1B). Conversely, this protein was
upregulated in benign thyroid tumors and in carcinomas
(p=0.005 by Kruskal-Wallis test; Fig. 1B).
In follicular adenoma samples PRKAR2B was
highly expressed with an average immunohistochemistry
score of 6.3±1 (p<0.05 vs normal or hyperplastic
thyroid) (Fig.1B). As for benign tumors, all papillary or
follicular carcinomas revealed a generally elevated
expression of PRKAR2B subunit (averaged score =
4.9±1.1 and 6.1±1.3, respectively) although its staining
was highly heterogeneous between specimens (Fig.1B
and Table 1). 
In anaplastic carcinomas PRKAR2B expression was
similar to that observed in both papillary and follicular
carcinomas (mean immunohistochemistry score =
5.2±2.2) (Fig.1B, Table 1).
PKA regulatory subunits expression and clinical
phenotype
As far as clinical and pathological phenotype in
differentiated thyroid carcinomas was concerned, both
PRKAR2B and PRKAR1A expression did not correlate
with sex or patients’ age at presentation. A marginal
upregulation of PRKAR1A was observed in papillary or
follicular carcinomas with metastatic lymph nodes
(average score N0 = 2.6±0.4, mean score N1 = 4.2±0.9;
Fig. 2A). Considering only tumors without lymph nodes
involvement (N0), a significant reduction of PRKAR1A
expression was observed in papillary or follicular
carcinoma of less than 2 cm in size (T1) in comparison
with the those bigger than 2 cm in size (>T1) (mean
immunohistochemistry score = 1.6±1.8 vs 3.5±1.6;
p=0.03 by Mann-Whitney U test; Fig.2B). Conversely,
PRKAR2B displayed an opposite though not significant
expression pattern in the aforementioned categories of
thyroid tumours (Fig. 2A,B).
Discussion
This study describes the expression of the two main
regulatory subunits of PKA in a relevant series of
neoplastic and non-neoplastic thyroid samples and
provides evidence for a specific expression pattern of
these subunits in different pathological conditions. 
TSH is the key modulator of thyroid cell growth,
function and differentiation, most of these effects being
mediated by the increase of intracellular cAMP
concentration. Although in non-endocrine cells cAMP
increases are generally associated with differentiation
and growth inhibition, in thyrocytes cAMP pathway
mediate proliferative signals. Indeed, the rationale for
TSH suppressive post-surgical treatment in patients with
thyroid cancers is based on these biological actions of
TSH. 
The consideration that most cAMP effects occur
through the activation of PKA and that the expression of
the two regulatory subunits PRKAR1A and PRKAR2B,
which are involved in the specific activation of PKA1
and PKA2, varies considerably during tumoral
transformation, led us to investigate the relative
expression of these subunits in thyroid neoplastic and
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4Fig. 1. Representative immunhistochemistry pictures for PRKAR isoforms 1A (A) and 1B (B) expression in normal thyroid (NT), nodular hyperplasia
(H), follicular adenoma (FA), papillary carcinoma (PC), and anaplastic carcinoma (AC) specimens. The arrow in normal thyroid (A) indicates a vessel
used as internal positive control. PRKAR1A and PRKAR2B immunoreactivities were graded according to an immunohistochemical score (IHC score,
range from 0 to 9 units) that is the product of the percentage of positive cells for the intensity of the staining (see Material and Methods). The
quantification of the IHC scores in normal or pathological thyroid samples is provided. *, p<0.05; **, p<0.01; ***, p<0.001 by Dunns post-test. A: NT, x
20; H, x 4; FA, x 10, PC, AC, x 40. B: NT, H, x 4; FA, x 10; PC, AC, x 40.
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non-neoplastic tissues. Indeed, the specific role of PKA
isoenzymes on thyroid cell proliferation is still
controversial and data supporting a major impact of
PKA1 or PKA2 mostly derive from studies carried out
on thyroid cell lines (Calebiro et al., 2006; Cho-Chung et
al., 1995; Porcellini et al., 2003). 
The present study showed that normal and
hyperplastic thyroid tissues were characterized by a low
expression of PRKAR1A and PRKAR2B, whereas both
subunits were significantly overexpressed in adenomas
and carcinomas. However, the pattern of expression of
PRKAR1A was strongly dependent on the histotypes,
being higher in anaplastic carcinomas in comparison to
differentiated carcinomas and hyperplastic or normal
thyroid tissues. Moreover, it is worth noting that in the
present series increased PRKAR1A expression was
found to be significantly associated with large
carcinomas (T2, T3) compared with T1 carcinomas,
without considering anaplastic carcinomas that were all
T4 stage. Conversely, the increase in PRKAR2B
expression did not correlate with cell differentiation,
being similar in follicular adenomas and follicular,
papillary and anaplastic cancers. 
Taken together these data it is tempting to speculate
that the increased levels of PRKAR1A and PRKAR2B
detected in thyroid neoplasia, and in particular increased
levels of PRKAR1A in anaplastic cancers, might result
in abnormal PKA activation. Data concerning PKA
activity and cAMP dependent signalling in human
thyroid cancers are few and mainly focused on cancers
bearing inactivating mutations of PRKAR1A gene
leading to premature termination and loss of the
predicted protein (Cho-Chung et al., 1995). Therefore,
additional functional studies are needed to understand
the biological impact of increased PRKAR1A expression
on thyroid tumorigenesis.
We found that normal thyroid tissues taken at
surgery as far as possible from neoplasia express low
levels of both PKA regulatory subunits. In particular,
absent or weak immunoreactivity for PRKAR2B was
detected in non-neoplastic tissues, while a weak
PKAR1A immunoreactivity was detectable in either
normal or hyperplastic thyroid samples. 
Interestingly our study evidences a significant
increase in R1A subunit expression in neoplastic
thyroids, including anaplastic carcinomas. 
More importantly, higher R1A expression was
significantly related to larger tumors in all the samples
analyzed and this pattern of immunoreactivity was
comparable to nodular hyperplasia.
When considering benign follicular adenomas,
PRKAR1A showed a slight but significant increase in
immunoreactivity compared to normal thyroid
specimens. Moreover, PRKAR2B was highly expressed
and was higher in comparison with PRKAR1A.
In this study, we demonstrated that PRKAR1A
expression might be an index of malignancy for thyroid
cancer, in particular in undifferentiated (anaplastic)
tumors and in cases where tumor size is more than 2 cm,
and that PRKAR2B expression, even if it did not
correlate with cell differentiation, might be a useful
marker for distinguishing thyroid hyperplasia from
tumors.
To our knowledge, this is the first evaluation of PKA
regulatory elements in a relevant series of patients with
different pathological conditions, even if more functional
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Fig. 2. Immunoreactivity scores for PRKAR1A (filled columns) or PRKAR2B (striped columns) in papillary and follicular thyroid carcinomas according to
lymph node status (N, A) or tumor size (T, B). *, p= 0.03 by Mann-Whitney U test. 
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studies of PRKAR1A in thyroid cancer are needed to
validate its role as a index of malignancy for these
neoplasms.
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